Renascience

Renascience OCF Margin

The Operating Cash Flow Margin of Renascience (4889.T) as of Nov 19, 2026 is -424.93 %. In the previous year, Operating Cash Flow Margin was -132.89 % — a change of 219.75% (lower).

OCF Margin

-424.93 %

YoY

219.75%

Last updated:

Operating Cash Flow Margin of Renascience is 2026 -424.93 % . Operating Cash Flow Margin of Renascience was 2025 -132.89 % . It decreases by 219.75% lower compared to the previous year.

The Renascience OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2020
-247.66 JPY
Jan 1, 2021
-42.54 JPY
Jan 1, 2022
-165.43 JPY
Jan 1, 2023
-283.10 JPY
Jan 1, 2024
-118.72 JPY
Jan 1, 2025
-132.89 JPY
Jan 1, 2026
-424.93 JPY
The Renascience OCF Margin history
YEAROCF MarginYoY
-424.93 %+219.75%
-132.89 %+11.94%
-118.72 %-58.06%
-283.10 %+71.13%
-165.43 %+288.85%
-42.54 %-82.82%
-247.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Operating Cash Flow Margin of Renascience is -424.93 % in 2026.

Operating Cash Flow Margin of Renascience changed from -132.89 % to -424.93 %, representing a 219.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Renascience since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Renascience

All Key Metrics — Renascience